Explore more about: Prostate Cancer

Study describes the use of restriction spectrum imaging as a biomarker that enhances the ability of MRI to differentiate aggressive cancer from benign tumors.

Researchers revealed that radiotracer PET/CT scans that targets prostate-specific membrane antigen was best at detecting metastatic prostate cancer.